These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 7748463)

  • 1. The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation.
    Münch G; Taneli Y; Schraven E; Schindler U; Schinzel R; Palm D; Riederer P
    J Neural Transm Park Dis Dement Sect; 1994; 8(3):193-208. PubMed ID: 7748463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of tenilsetam on the Maillard reaction.
    Shoda H; Miyata S; Liu BF; Yamada H; Ohara T; Suzuki K; Oimomi M; Kasuga M
    Endocrinology; 1997 May; 138(5):1886-92. PubMed ID: 9112383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of advanced glycation end-products and AGE-inhibitors on nucleation-dependent polymerization of beta-amyloid peptide.
    Münch G; Mayer S; Michaelis J; Hipkiss AR; Riederer P; Müller R; Neumann A; Schinzel R; Cunningham AM
    Biochim Biophys Acta; 1997 Feb; 1360(1):17-29. PubMed ID: 9061036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation Into the Effects of Tenilsetam on Markers of Neuroinflammation in GFAP-IL6 Mice.
    Gyengesi E; Liang H; Millington C; Sonego S; Sirijovski D; Gunawardena D; Dhananjayan K; Venigalla M; Niedermayer G; Münch G
    Pharm Res; 2018 Jan; 35(1):22. PubMed ID: 29305671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenilsetam prevents early diabetic retinopathy without correcting pericyte loss.
    Hoffmann J; Alt A; Lin J; Lochnit G; Schubert U; Schleicher E; Chavakis T; Brownlee M; Van der Woude FJ; Preissner KT; Hammes HP
    Thromb Haemost; 2006 Apr; 95(4):689-95. PubMed ID: 16601840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?
    Dukic-Stefanovic S; Schinzel R; Riederer P; Münch G
    Biogerontology; 2001; 2(1):19-34. PubMed ID: 11708614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the Maillard reaction in other pathologies: Alzheimer's disease.
    Colaco CA; Ledesma MD; Harrington CR; Avila J
    Nephrol Dial Transplant; 1996; 11 Suppl 5():7-12. PubMed ID: 9044299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs)].
    Thome J; Kornhuber J; Münch G; Schinzel R; Taneli Y; Zielke B; Rösler M; Riederer P
    Nervenarzt; 1996 Nov; 67(11):924-9. PubMed ID: 9064552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation endproducts in ageing and Alzheimer's disease.
    Münch G; Thome J; Foley P; Schinzel R; Riederer P
    Brain Res Brain Res Rev; 1997 Feb; 23(1-2):134-43. PubMed ID: 9063589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
    Yamagishi S; Taguchi K; Fukami K
    Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide.
    Loske C; Gerdemann A; Schepl W; Wycislo M; Schinzel R; Palm D; Riederer P; Münch G
    Eur J Biochem; 2000 Jul; 267(13):4171-8. PubMed ID: 10866821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
    Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
    Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biochemical properties and clinical significance of protein glycation products].
    Staniszewska M; Gamian A
    Postepy Hig Med Dosw; 2003; 57(2):123-47. PubMed ID: 12866352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease.
    Smith MA; Richey PL; Taneda S; Kutty RK; Sayre LM; Monnier VM; Perry G
    Ann N Y Acad Sci; 1994 Nov; 738():447-54. PubMed ID: 7832455
    [No Abstract]   [Full Text] [Related]  

  • 15. An immunochemical study on tau glycation in paired helical filaments.
    Ko LW; Ko EC; Nacharaju P; Liu WK; Chang E; Kenessey A; Yen SH
    Brain Res; 1999 Jun; 830(2):301-13. PubMed ID: 10366687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease.
    Wong A; Lüth HJ; Deuther-Conrad W; Dukic-Stefanovic S; Gasic-Milenkovic J; Arendt T; Münch G
    Brain Res; 2001 Nov; 920(1-2):32-40. PubMed ID: 11716809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The carbonyl scavengers aminoguanidine and tenilsetam protect against the neurotoxic effects of methylglyoxal.
    Webster J; Urban C; Berbaum K; Loske C; Alpar A; Gärtner U; de Arriba SG; Arendt T; Münch G
    Neurotox Res; 2005; 7(1-2):95-101. PubMed ID: 15639802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
    Takeuchi M; Yamagishi S
    Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein glycation, diabetes, and aging.
    Ulrich P; Cerami A
    Recent Prog Horm Res; 2001; 56():1-21. PubMed ID: 11237208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease--a target for neuroprotective treatment strategies?
    Münch G; Deuther-Conrad W; Gasic-Milenkovic J
    J Neural Transm Suppl; 2002; (62):303-7. PubMed ID: 12456073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.